EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$11.15 USD
-0.13 (-1.15%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $11.16 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.15 USD
-0.13 (-1.15%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $11.16 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
Zacks News
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -200.00% and 0.22%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 9.09% and 46.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Surges: Stock Moves 7.4% Higher
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.00% and 7.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 25.00% and 12.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Will EyePoint Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in EyePoint.
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 0.00% and -47.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will EyePoint Pharmaceuticals (EYPT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 15.38% and 6.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -23.08% and -45.55%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will EyePoint Pharmaceuticals (EYPT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 14.29% and 272.82%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: EyePoint Pharmaceuticals (EYPT) Q2 Earnings Expected to Decline
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to EyePoint Pharmaceuticals (EYPT) stock based on the movements in the options market lately.
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -46.15% and -30.57%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will EyePoint Pharmaceuticals (EYPT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq
by Zacks Equity Research
EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.
EyePoint Pharmaceuticals (EYPT) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to EyePoint Pharmaceuticals (EYPT) stock based on the movements in the options market lately.
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -111.11% and 6.72%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Q4 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will EyePoint Pharmaceuticals (EYPT) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in EyePoint Pharmaceuticals, Inc. (EYPT)